{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T17:47:40Z","timestamp":1787593660782,"version":"build-2736575974"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,4,20]],"date-time":"2017-04-20T00:00:00Z","timestamp":1492646400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Canadian Institutes of Health Research and the Canadian Foundation for AIDS Research"},{"name":"Laboratory Medicine and Pathobiology Program at the University of Toronto"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy - Nucleic Acids"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.omtn.2017.04.017","type":"journal-article","created":{"date-parts":[[2017,4,22]],"date-time":"2017-04-22T11:00:20Z","timestamp":1492858820000},"page":"387-395","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Further Characterization of the Bifunctional HIV Entry Inhibitor sCD4-FI T45"],"prefix":"10.1016","volume":"7","author":[{"given":"Alexander","family":"Falkenhagen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadhna","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtn.2017.04.017_bib1","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nature01470","article-title":"Antibody neutralization and escape by HIV-1","volume":"422","author":"Wei","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2017.04.017_bib2","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/nature13808","article-title":"Structure and immune recognition of trimeric pre-fusion HIV-1 Env","volume":"514","author":"Pancera","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2017.04.017_bib3","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1126\/science.aad2450","article-title":"Cryo-EM structure of a native, fully glycosylated, cleaved HIV-1 envelope trimer","volume":"351","author":"Lee","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.omtn.2017.04.017_bib4","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1016\/j.celrep.2016.07.074","article-title":"Holes in the glycan shield of the native HIV envelope are a target of trimer-elicited neutralizing antibodies","volume":"16","author":"McCoy","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.omtn.2017.04.017_bib5","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1126\/science.1207227","article-title":"Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding","volume":"333","author":"Scheid","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.omtn.2017.04.017_bib6","doi-asserted-by":"crossref","first-page":"8954","DOI":"10.1128\/JVI.00754-11","article-title":"Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01","volume":"85","author":"Li","year":"2011","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.omtn.2017.04.017_bib7","doi-asserted-by":"crossref","first-page":"319ra206","DOI":"10.1126\/scitranslmed.aad5752","article-title":"Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection","volume":"7","author":"Lynch","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omtn.2017.04.017_bib8","doi-asserted-by":"crossref","first-page":"43170","DOI":"10.1074\/jbc.M112.399402","article-title":"A single residue within the V5 region of HIV-1 envelope facilitates viral escape from the broadly neutralizing monoclonal antibody VRC01","volume":"287","author":"Guo","year":"2012","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.omtn.2017.04.017_bib9","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1126\/science.3500514","article-title":"Blocking of HIV-1 infectivity by a soluble, secreted form of the CD4 antigen","volume":"238","author":"Smith","year":"1987","journal-title":"Science"},{"key":"10.1016\/j.omtn.2017.04.017_bib10","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1073\/pnas.85.7.2357","article-title":"A soluble recombinant polypeptide comprising the amino-terminal half of the extracellular region of the CD4 molecule contains an active binding site for human immunodeficiency virus","volume":"85","author":"Berger","year":"1988","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2017.04.017_bib11","doi-asserted-by":"crossref","first-page":"4201","DOI":"10.1128\/JVI.03608-14","article-title":"HIV-1 fitness cost associated with escape from the VRC01 class of CD4 binding site neutralizing antibodies","volume":"89","author":"Lynch","year":"2015","journal-title":"J.\u00a0Virol."},{"issue":"4A","key":"10.1016\/j.omtn.2017.04.017_bib12","doi-asserted-by":"crossref","first-page":"22S","DOI":"10.1016\/0002-9343(91)90407-O","article-title":"Relative resistance of primary HIV-1 isolates to neutralization by soluble CD4","volume":"90","author":"Daar","year":"1991","journal-title":"Am. J. Med."},{"key":"10.1016\/j.omtn.2017.04.017_bib13","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1073\/pnas.88.2.512","article-title":"Envelope glycoproteins from biologically diverse isolates of immunodeficiency viruses have widely different affinities for CD4","volume":"88","author":"Ivey-Hoyle","year":"1991","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2017.04.017_bib14","doi-asserted-by":"crossref","first-page":"7802","DOI":"10.1073\/pnas.88.17.7802","article-title":"Envelope proteins from clinical isolates of human immunodeficiency virus type 1 that are refractory to neutralization by soluble CD4 possess high affinity for the CD4 receptor","volume":"88","author":"Brighty","year":"1991","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2017.04.017_bib15","doi-asserted-by":"crossref","first-page":"e1000360","DOI":"10.1371\/journal.ppat.1000360","article-title":"Soluble CD4 and CD4-mimetic compounds inhibit HIV-1 infection by induction of a short-lived activated state","volume":"5","author":"Haim","year":"2009","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.omtn.2017.04.017_bib16","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/0092-8674(86)90778-6","article-title":"Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III\/LAV, the retrovirus of AIDS","volume":"45","author":"Starcich","year":"1986","journal-title":"Cell"},{"key":"10.1016\/j.omtn.2017.04.017_bib17","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/31405","article-title":"Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody","volume":"393","author":"Kwong","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2017.04.017_bib18","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.1128\/JVI.67.7.3978-3988.1993","article-title":"Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding","volume":"67","author":"Thali","year":"1993","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.omtn.2017.04.017_bib19","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/384179a0","article-title":"CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5","volume":"384","author":"Wu","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2017.04.017_bib20","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1128\/JVI.77.5.2859-2865.2003","article-title":"Neutralization of human immunodeficiency virus type 1 by sCD4-17b, a single-chain chimeric protein, based on sequential interaction of gp120 with CD4 and coreceptor","volume":"77","author":"Dey","year":"2003","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.omtn.2017.04.017_bib21","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1742-4690-7-11","article-title":"sCD4-17b bifunctional protein: extremely broad and potent neutralization of HIV-1 Env pseudotyped viruses from genetically diverse primary isolates","volume":"7","author":"Lagenaur","year":"2010","journal-title":"Retrovirology"},{"key":"10.1016\/j.omtn.2017.04.017_bib22","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.virol.2010.09.029","article-title":"The effect of sCD4 on the binding and accessibility of HIV-1 gp41 MPER epitopes to human monoclonal antibodies","volume":"408","author":"Peachman","year":"2010","journal-title":"Virology"},{"key":"10.1016\/j.omtn.2017.04.017_bib23","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1128\/JVI.77.3.1666-1671.2003","article-title":"Peptides trap the human immunodeficiency virus type 1 envelope glycoprotein fusion intermediate at two sites","volume":"77","author":"He","year":"2003","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.omtn.2017.04.017_bib24","doi-asserted-by":"crossref","first-page":"7573","DOI":"10.1074\/jbc.M211154200","article-title":"The prefusogenic intermediate of HIV-1 gp41 contains exposed C-peptide regions","volume":"278","author":"Koshiba","year":"2003","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.omtn.2017.04.017_bib25","doi-asserted-by":"crossref","first-page":"5036","DOI":"10.1073\/pnas.0307953101","article-title":"Small-molecule inhibitors of HIV-1 entry block receptor-induced conformational changes in the viral envelope glycoproteins","volume":"101","author":"Si","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2017.04.017_bib26","doi-asserted-by":"crossref","first-page":"26941","DOI":"10.1074\/jbc.M109.004416","article-title":"Detailed mechanistic insights into HIV-1 sensitivity to three generations of fusion inhibitors","volume":"284","author":"Eggink","year":"2009","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.omtn.2017.04.017_bib27","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1097\/01.aids.0000247112.36091.f8","article-title":"An anti-HIV microbicide engineered in commensal bacteria: secretion of HIV-1 fusion inhibitors by lactobacilli","volume":"20","author":"Pusch","year":"2006","journal-title":"AIDS"},{"key":"10.1016\/j.omtn.2017.04.017_bib28","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/gt.2013.70","article-title":"A novel gene therapy strategy using secreted multifunctional anti-HIV proteins to confer protection to gene-modified and unmodified target cells","volume":"21","author":"Falkenhagen","year":"2014","journal-title":"Gene Ther."},{"key":"10.1016\/j.omtn.2017.04.017_bib29","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s12896-016-0288-3","article-title":"Lentiviral expression system for the purification of secreted proteins from human cell cultures","volume":"16","author":"Falkenhagen","year":"2016","journal-title":"BMC Biotechnol."},{"key":"10.1016\/j.omtn.2017.04.017_bib30","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1084\/jem.20030648","article-title":"HIV-1 cell to cell transfer across an Env-induced, actin-dependent synapse","volume":"199","author":"Jolly","year":"2004","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.omtn.2017.04.017_bib31","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1126\/science.1167525","article-title":"Quantitative 3D video microscopy of HIV transfer across T\u00a0cell virological synapses","volume":"323","author":"H\u00fcbner","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.omtn.2017.04.017_bib32","doi-asserted-by":"crossref","first-page":"e1004513","DOI":"10.1371\/journal.ppat.1004513","article-title":"Unique features of HIV-1 spread through T\u00a0cell virological synapses","volume":"10","author":"Alvarez","year":"2014","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.omtn.2017.04.017_bib33","doi-asserted-by":"crossref","first-page":"3516","DOI":"10.1128\/JVI.02651-09","article-title":"Virological synapse-mediated spread of human immunodeficiency virus type 1 between T\u00a0cells is sensitive to entry inhibition","volume":"84","author":"Martin","year":"2010","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.omtn.2017.04.017_bib34","doi-asserted-by":"crossref","first-page":"247","DOI":"10.7326\/0003-4819-112-4-247","article-title":"Recombinant soluble CD4 therapy in patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase I-II escalating dosage trial","volume":"112","author":"Schooley","year":"1990","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.omtn.2017.04.017_bib35","first-page":"145","article-title":"Phase I study of high-dose, intravenous rsCD4 in subjects with advanced HIV-1 infection","volume":"9","author":"Schacker","year":"1995","journal-title":"J.\u00a0Acquir. Immune Defic. Syndr. Hum. Retrovirol."},{"key":"10.1016\/j.omtn.2017.04.017_bib36","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/344667a0","article-title":"Biological properties of a CD4 immunoadhesin","volume":"344","author":"Byrn","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2017.04.017_bib37","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1089\/aid.1995.11.533","article-title":"Expression and characterization of CD4-IgG2, a novel heterotetramer that neutralizes primary HIV type 1 isolates","volume":"11","author":"Allaway","year":"1995","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"10.1016\/j.omtn.2017.04.017_bib38","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1128\/AAC.35.12.2580","article-title":"Phase 1 study of recombinant human CD4-immunoglobulin G therapy of patients with AIDS and AIDS-related complex","volume":"35","author":"Hodges","year":"1991","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.omtn.2017.04.017_bib39","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.jaci.2006.10.045","article-title":"Nonlinear pharmacokinetics of high-dose recombinant fusion protein CD4-IgG2 (PRO 542) observed in HIV-1-infected children","volume":"119","author":"Fletcher","year":"2007","journal-title":"J.\u00a0Allergy Clin. Immunol."},{"key":"10.1016\/j.omtn.2017.04.017_bib40","doi-asserted-by":"crossref","first-page":"4413","DOI":"10.1128\/JVI.69.7.4413-4422.1995","article-title":"Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates","volume":"69","author":"Sullivan","year":"1995","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.omtn.2017.04.017_bib41","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/j.1365-3083.1995.tb03528.x","article-title":"Enhancement of infectivity of a non-syncytium inducing HIV-1 by sCD4 and by human antibodies that neutralize syncytium inducing HIV-1","volume":"41","author":"Schutten","year":"1995","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.omtn.2017.04.017_bib42","doi-asserted-by":"crossref","first-page":"4394","DOI":"10.1128\/JVI.06973-11","article-title":"PGV04, an HIV-1 gp120 CD4 binding site antibody, is broad and potent in neutralization but does not induce conformational changes characteristic of CD4","volume":"86","author":"Falkowska","year":"2012","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.omtn.2017.04.017_bib43","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/nature10347","article-title":"Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy","volume":"477","author":"Sigal","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2017.04.017_bib44","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1084\/jem.20131244","article-title":"Broadly neutralizing antibodies that inhibit HIV-1 cell to cell transmission","volume":"210","author":"Malbec","year":"2013","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.omtn.2017.04.017_bib45","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.cell.2009.02.046","article-title":"HIV enters cells via endocytosis and dynamin-dependent fusion with endosomes","volume":"137","author":"Miyauchi","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.omtn.2017.04.017_bib46","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/1742-4690-9-104","article-title":"A bivalent recombinant protein inactivates HIV-1 by targeting the gp41 prehairpin fusion intermediate induced by CD4 D1D2 domains","volume":"9","author":"Lu","year":"2012","journal-title":"Retrovirology"},{"key":"10.1016\/j.omtn.2017.04.017_bib47","doi-asserted-by":"crossref","first-page":"9395","DOI":"10.1128\/JVI.05119-11","article-title":"Engineered single human CD4 domains as potent HIV-1 inhibitors and components of vaccine immunogens","volume":"85","author":"Chen","year":"2011","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.omtn.2017.04.017_bib48","doi-asserted-by":"crossref","first-page":"6685","DOI":"10.1128\/JVI.00474-15","article-title":"Novel CD4-based bispecific chimeric antigen receptor designed for enhanced anti-HIV potency and absence of HIV entry receptor activity","volume":"89","author":"Liu","year":"2015","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.omtn.2017.04.017_bib49","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/nature14411","article-title":"Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117","volume":"522","author":"Caskey","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2017.04.017_bib50","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/nature17677","article-title":"A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges","volume":"533","author":"Gautam","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2017.04.017_bib51","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nature10660","article-title":"Antibody-based protection against HIV infection by vectored immunoprophylaxis","volume":"481","author":"Balazs","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2017.04.017_bib52","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nature14264","article-title":"AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges","volume":"519","author":"Gardner","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2017.04.017_bib53","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1128\/JVI.72.4.2855-2864.1998","article-title":"Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1","volume":"72","author":"Platt","year":"1998","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.omtn.2017.04.017_bib54","doi-asserted-by":"crossref","first-page":"8358","DOI":"10.1128\/JVI.74.18.8358-8367.2000","article-title":"Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120","volume":"74","author":"Derdeyn","year":"2000","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.omtn.2017.04.017_bib55","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1128\/AAC.46.6.1896-1905.2002","article-title":"Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy","volume":"46","author":"Wei","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.omtn.2017.04.017_bib56","doi-asserted-by":"crossref","first-page":"12585","DOI":"10.1128\/JVI.01726-08","article-title":"Identification of gammaretroviruses constitutively released from cell lines used for human immunodeficiency virus research","volume":"82","author":"Takeuchi","year":"2008","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.omtn.2017.04.017_bib57","doi-asserted-by":"crossref","first-page":"8289","DOI":"10.1128\/JVI.00709-09","article-title":"Evidence that ecotropic murine leukemia virus contamination in TZM-bl cells does not affect the outcome of neutralizing antibody assays with human immunodeficiency virus type 1","volume":"83","author":"Platt","year":"2009","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.omtn.2017.04.017_bib58","doi-asserted-by":"crossref","first-page":"7060","DOI":"10.1128\/JVI.67.12.7060-7066.1993","article-title":"Characterization of stable Chinese hamster ovary cells expressing wild-type, secreted, and glycosylphosphatidylinositol-anchored human immunodeficiency virus type 1 envelope glycoprotein","volume":"67","author":"Weiss","year":"1993","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.omtn.2017.04.017_bib59","doi-asserted-by":"crossref","first-page":"28745","DOI":"10.1074\/jbc.274.40.28745","article-title":"Enhanced expression, native purification, and characterization of CCR5, a principal HIV-1 coreceptor","volume":"274","author":"Mirzabekov","year":"1999","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.omtn.2017.04.017_bib60","doi-asserted-by":"crossref","first-page":"10108","DOI":"10.1128\/JVI.79.16.10108-10125.2005","article-title":"Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies","volume":"79","author":"Li","year":"2005","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.omtn.2017.04.017_bib61","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.virol.2008.12.032","article-title":"Highly complex neutralization determinants on a monophyletic lineage of newly transmitted subtype C HIV-1 Env clones from India","volume":"385","author":"Kulkarni","year":"2009","journal-title":"Virology"},{"key":"10.1016\/j.omtn.2017.04.017_bib62","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1089\/aid.1994.10.359","article-title":"Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization","volume":"10","author":"Buchacher","year":"1994","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"10.1016\/j.omtn.2017.04.017_bib63","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1089\/aid.1994.10.1651","article-title":"A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1","volume":"10","author":"Purtscher","year":"1994","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"10.1016\/j.omtn.2017.04.017_bib64","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1097\/00002030-199606000-00003","article-title":"Restricted antigenic variability of the epitope recognized by the neutralizing gp41 antibody 2F5","volume":"10","author":"Purtscher","year":"1996","journal-title":"AIDS"},{"key":"10.1016\/j.omtn.2017.04.017_bib65","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1126\/science.1187659","article-title":"Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1","volume":"329","author":"Wu","year":"2010","journal-title":"Science"},{"issue":"W1","key":"10.1016\/j.omtn.2017.04.017_bib66","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkv404","article-title":"CATNAP: a tool to compile, analyze and tally neutralizing antibody panels","volume":"43","author":"Yoon","year":"2015","journal-title":"Nucleic Acids Res."}],"container-title":["Molecular Therapy - Nucleic Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253117301683?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253117301683?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T03:08:49Z","timestamp":1601953729000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2162253117301683"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":66,"alternative-id":["S2162253117301683"],"URL":"https:\/\/doi.org\/10.1016\/j.omtn.2017.04.017","relation":{},"ISSN":["2162-2531"],"issn-type":[{"value":"2162-2531","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Further Characterization of the Bifunctional HIV Entry Inhibitor sCD4-FIT45","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy - Nucleic Acids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtn.2017.04.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors.","name":"copyright","label":"Copyright"}]}}